Disease modifiers that are independent from BRCA1/2, de novo mutations, or limited family structures may explain the finding that a subgroup of BRCA1/2-positive patients with ovarian cancer did not show a positive family history. The gene discussed is BRCA1; the disease is ovarian carcinoma.